JP2011510007A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011510007A5 JP2011510007A5 JP2010543197A JP2010543197A JP2011510007A5 JP 2011510007 A5 JP2011510007 A5 JP 2011510007A5 JP 2010543197 A JP2010543197 A JP 2010543197A JP 2010543197 A JP2010543197 A JP 2010543197A JP 2011510007 A5 JP2011510007 A5 JP 2011510007A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- compound
- independently
- disease
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 9
- 208000002193 Pain Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 230000036407 pain Effects 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 208000009935 visceral pain Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 claims 2
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000013078 crystal Substances 0.000 claims 2
- 150000004820 halides Chemical class 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010018307 Glaucoma and ocular hypertension Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000033463 Ischaemic neuropathy Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 206010028735 Nasal congestion Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 206010061323 Optic neuropathy Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000004880 Polyuria Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 206010048010 Withdrawal syndrome Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000004410 intraocular pressure Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000020911 optic nerve disease Diseases 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2215808P | 2008-01-18 | 2008-01-18 | |
| US61/022,158 | 2008-01-18 | ||
| PCT/US2009/030886 WO2009091759A1 (en) | 2008-01-18 | 2009-01-14 | Selective subtype alpha 2 adrenergic agents and methods for use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011510007A JP2011510007A (ja) | 2011-03-31 |
| JP2011510007A5 true JP2011510007A5 (https=) | 2012-03-01 |
| JP5480819B2 JP5480819B2 (ja) | 2014-04-23 |
Family
ID=40451425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010543197A Expired - Fee Related JP5480819B2 (ja) | 2008-01-18 | 2009-01-14 | 選択的サブタイプアルファ２アドレナリンアゴニスト及びその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8362022B2 (https=) |
| EP (1) | EP2240468B1 (https=) |
| JP (1) | JP5480819B2 (https=) |
| BR (1) | BRPI0906925A2 (https=) |
| CA (1) | CA2712262A1 (https=) |
| DK (1) | DK2240468T3 (https=) |
| ES (1) | ES2442298T3 (https=) |
| WO (1) | WO2009091759A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8809379B2 (en) * | 2008-01-18 | 2014-08-19 | Allergan, Inc. | Selective subtype alpha 2 adrenergic agents and methods for use thereof |
| EP2242753B1 (en) * | 2008-01-18 | 2015-04-08 | Allergan, Inc. | Oxazolidine and thiazolidine selective subtype alpha 2 adrenergic agents and methods for use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO750876L (https=) * | 1974-03-28 | 1975-09-30 | Bayer Ag | |
| JPS61158968A (ja) * | 1984-12-29 | 1986-07-18 | Daicel Chem Ind Ltd | フエナシル誘導体 |
| GB8610909D0 (en) * | 1986-05-03 | 1986-06-11 | Beecham Group Plc | Compounds |
| US5212176A (en) | 1990-06-29 | 1993-05-18 | Abbott Laboratories | R(+)-terazosin |
| WO2005005394A2 (en) * | 2003-07-09 | 2005-01-20 | F.Hoffmann-La Roche Ag | Thiophenylaminoimidazolines as prostaglandin i2 antagonists |
| MXPA06006501A (es) | 2003-12-23 | 2006-08-23 | Basf Ag | Compuestos de 1-(azolin-2-il)amino-1,2-difeniletano para combatir insectos, aracnidos y nematodos. |
| DE602005013793D1 (de) * | 2004-07-27 | 2009-05-20 | Astellas Pharma Inc | Thiazolderivate mit vap-1-hemmender wirkung |
| WO2008123821A1 (en) * | 2007-03-01 | 2008-10-16 | Albireo Ab | 4, 5-dihydro-lh-imidazol-2-amine derivatives for use in the treatment of respiratory, cardiovascular, neurological or gastrointestinal disorders |
-
2009
- 2009-01-14 JP JP2010543197A patent/JP5480819B2/ja not_active Expired - Fee Related
- 2009-01-14 WO PCT/US2009/030886 patent/WO2009091759A1/en not_active Ceased
- 2009-01-14 US US12/811,773 patent/US8362022B2/en not_active Expired - Fee Related
- 2009-01-14 ES ES09702233.9T patent/ES2442298T3/es active Active
- 2009-01-14 DK DK09702233.9T patent/DK2240468T3/da active
- 2009-01-14 EP EP09702233.9A patent/EP2240468B1/en not_active Not-in-force
- 2009-01-14 BR BRPI0906925A patent/BRPI0906925A2/pt not_active IP Right Cessation
- 2009-01-14 CA CA2712262A patent/CA2712262A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011509297A5 (https=) | ||
| JP2011522774A5 (https=) | ||
| JP2004517852A5 (https=) | ||
| JP2007516941A5 (https=) | ||
| JP6262732B2 (ja) | Ｎ型カルシウムチャネル遮断剤としての置換ピラゾール | |
| BR112012015168A2 (pt) | "derivados de benzamida substituída". | |
| CN1486301A (zh) | 具有cb1－拮抗活性的4,5－二氢－1h－吡唑衍生物 | |
| JP2015531764A5 (https=) | ||
| JP5453312B2 (ja) | アルファ２ｂおよび／またはアルファ２ｃアドレナリンレセプターのサブタイプ選択性モジュレーターである置換アリール‐（イミダゾール）‐メチル）‐フェニル化合物 | |
| JP2009530281A5 (https=) | ||
| ZA200408506B (en) | 5HT2c receptor modulators | |
| JP2012515166A5 (https=) | ||
| RU2008108219A (ru) | Соединения, представляющие собой 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенный пиридин, для лечения неврологических, психиатрических или болевыхрасстройств | |
| JP2019525939A5 (https=) | ||
| WO2007016353A3 (en) | Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists | |
| JP2011517443A5 (https=) | ||
| AR070512A1 (es) | Derivados monoamina como antagonistas del receptor de orexina , proceso para la preparacion de dichos compuestos , medicamentos que los contienen y uso de los mismos | |
| JP2016514117A5 (https=) | ||
| EP1339406A2 (en) | Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders | |
| JP2012508275A5 (https=) | ||
| JP2011510007A5 (https=) | ||
| JP2009528317A5 (https=) | ||
| JP2011510013A5 (https=) | ||
| JP2011510008A5 (https=) | ||
| JP2015521643A5 (https=) |